The stock of Intersect ENT Inc (NASDAQ:XENT) is a huge mover today! About 2.26 million shares traded hands or 604.78% up from the average. Intersect ENT Inc (NASDAQ:XENT) has declined 56.05% since April 1, 2016 and is downtrending. It has underperformed by 57.27% the S&P500.
The move comes after 5 months positive chart setup for the $149.51 million company. It was reported on Nov, 3 by Barchart.com. We have $22.32 PT which if reached, will make NASDAQ:XENT worth $206.32M more.
Intersect ENT Inc (NASDAQ:XENT) Ratings Coverage
Out of 7 analysts covering Intersect ENT (NASDAQ:XENT), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Intersect ENT has been the topic of 8 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating given on Tuesday, September 29 by Piper Jaffray. As per Monday, August 17, the company rating was maintained by Canaccord Genuity. The firm has “Neutral” rating given on Wednesday, November 2 by JP Morgan. The firm earned “Outperform” rating on Tuesday, March 29 by Northland Capital. The stock of Intersect ENT Inc (NASDAQ:XENT) has “Hold” rating given on Thursday, October 6 by Deutsche Bank. Canaccord Genuity maintained the shares of XENT in a report on Thursday, October 1 with “Buy” rating. The stock has “Buy” rating given by Bank of America on Friday, December 18.
According to Zacks Investment Research, “Intersect ENT, Inc. is a commercial drug-device company. The Company’s initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California.”
More news for Intersect ENT Inc (NASDAQ:XENT) were recently published by: Fool.com, which released: “Here’s Why Intersect ENT, Inc.’s Stock Cratered Today” on November 05, 2015. Fool.com‘s article titled: “Why Intersect ENT Shares Are Crashing 31.6% Today” and published on May 06, 2016 is yet another important article.
XENT Company Profile
Intersect ENT, Inc., incorporated on October 6, 2003, is a commercial stage drug-device company. The Firm develops drugs for patients with ear, nose and throat (ENT) conditions. The Firm has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.